Impact of pharmaceutical intervention in women with epilepsy

Not Applicable

Completed

• Conditions: Epilepsy; Nervous System Diseases

• Registration Number: ISRCTN46864306
• Lead Sponsor: niversidad Nacional de Colombia (Colombia)

Brief Summary

2014 Results article in http://www.ncbi.nlm.nih.gov/pubmed/25358723 results 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35180569/ (added 21/02/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-06-07
• Study Completion: 2011-02-28
• Last Update Posted: 7 March 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 182

Inclusion Criteria

1. Female, over 18 years
2. Diagnosis of epilepsy for more than a year
3. In treatment with antiepileptic drugs
4. Having at least one crisis in the last year
5. Ability to comply with the directions of the study

Exclusion Criteria

1. Active major psychiatric disorder
2. Physical deficit (e.g., hemiplegia) or mental (e.g., mental retardation), preventing them from answering questionnaires
3. Drug/alcohol dependence
4. Involvement, earlier in the pharmaceutical care program of the institution

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of Life in Epilepsy Inventory-31 (QOLIE-31). Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months).

Secondary Outcome Measures

Name	Time	Method
<br> Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months):<br> 1. Liverpool Adverse Events Profile<br> 2. Spanish Center for Epidemiologic Studies, Depression Scale<br> 3. Drug related problems<br>